Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02876835




Registration number
NCT02876835
Ethics application status
Date submitted
19/08/2016
Date registered
24/08/2016
Date last updated
2/04/2024

Titles & IDs
Public title
Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND)
Scientific title
A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Darbepoetin Alfa
Secondary ID [1] 0 0
2016-000542-65
Secondary ID [2] 0 0
200808
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Anaemia 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Renal and Urogenital 0 0 0 0
Other renal and urogenital disorders
Blood 0 0 0 0
Anaemia

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Daprodustat
Treatment: Drugs - Darbepoetin alfa
Treatment: Drugs - Placebo
Treatment: Drugs - Iron Therapy

Experimental: Daprodustat - Participants will receive oral daprodustat once daily.

Active comparator: Darbepoetin alfa - Participants will be administered darbepoetin alfa subcutaneously (SC).


Treatment: Drugs: Daprodustat
The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.

Treatment: Drugs: Darbepoetin alfa
The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.

Treatment: Drugs: Placebo
Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).

Treatment: Drugs: Iron Therapy
Participants will receive supplemental iron therapy if ferritin is \<=100 ng/mL or TSAT is \<=20%. The investigator will choose the route of administration and dose of iron.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period (Non-inferiority Analysis)
Timepoint [1] 0 0
Up to 4.3 person-years for CV follow-up time period
Primary outcome [2] 0 0
Mean Change From Baseline in Hgb Levels Over the Evaluation Period (Week 28 to Week 52)
Timepoint [2] 0 0
Baseline (Pre-dose on Day 1) and evaluation period (Week 28 to Week 52)
Secondary outcome [1] 0 0
Time to First Occurrence of Adjudicated MACE During CV Events Follow-up Time Period (Superiority Analysis)
Timepoint [1] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [2] 0 0
Time to First Occurrence of Adjudicated MACE or Thromboembolic Event During CV Events Follow-up Time Period
Timepoint [2] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [3] 0 0
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure During CV Events Follow-up Time Period
Timepoint [3] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [4] 0 0
Time to First Occurrence of Chronic Kidney Disease (CKD) Progression During CV Events Follow-up Time Period
Timepoint [4] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [5] 0 0
Time to First Occurrence of Adjudicated All-Cause Mortality During Vital Status for Follow-up Time Period
Timepoint [5] 0 0
Up to 4.3 person-years for vital status follow-up time period
Secondary outcome [6] 0 0
Time to First Occurrence of Adjudicated CV Mortality During CV Events Follow-up Time Period
Timepoint [6] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [7] 0 0
Time to First Occurrence of Adjudicated Myocardial Infarction (MI) (Fatal and Non-Fatal) During CV Events Follow-up Time Period
Timepoint [7] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [8] 0 0
Time to First Occurrence of Adjudicated Stroke (Fatal and Non-Fatal) During CV Events Follow-up Time Period
Timepoint [8] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [9] 0 0
Number of Participants With Adjudicated MACE or Hospitalization for Heart Failure (Recurrent Events Analysis)
Timepoint [9] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [10] 0 0
Time to First Occurrence of Adjudicated CV Mortality or Non-Fatal MI During CV Events Follow-up Time Period
Timepoint [10] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [11] 0 0
Time to First Occurrence of All-Cause Hospitalization During CV Events Follow-up Time Period
Timepoint [11] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [12] 0 0
Time to First Occurrence of All-Cause Hospital Re-admission Within 30 Days During CV Events Follow-up Time Period
Timepoint [12] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [13] 0 0
Time to First Occurrence of Adjudicated MACE or Hospitalization for Heart Failure or Thromboembolic Events During CV Events Follow-up Time Period
Timepoint [13] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [14] 0 0
Time to First Occurrence of Adjudicated Hospitalization for Heart Failure During CV Events Follow-up Time Period
Timepoint [14] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [15] 0 0
Time to First Occurrence of Adjudicated Thromboembolic Events During CV Events Follow-up Time Period
Timepoint [15] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [16] 0 0
Time to First Occurrence of Confirmed 40% Decline in eGFR During CV Events Follow-up Time Period
Timepoint [16] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [17] 0 0
Time to First Occurrence of Chronic Dialysis During CV Events Follow-up Time Period
Timepoint [17] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [18] 0 0
Time to First Occurrence of Kidney Transplant During CV Events Follow-up Time Period
Timepoint [18] 0 0
Up to 4.3 person-years for CV follow-up time period
Secondary outcome [19] 0 0
Change From Baseline in Post-randomization Hgb Levels at Week 52
Timepoint [19] 0 0
Baseline (Pre-dose on Day 1) and Week 52
Secondary outcome [20] 0 0
Number of Hgb Responders in the Hgb Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52)
Timepoint [20] 0 0
Week 28 to Week 52
Secondary outcome [21] 0 0
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Non-inferiority Analysis
Timepoint [21] 0 0
Week 28 to Week 52
Secondary outcome [22] 0 0
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Evaluation Period (Week 28 to Week 52): Superiority Analysis
Timepoint [22] 0 0
Week 28 to Week 52
Secondary outcome [23] 0 0
Percentage of Time With Hgb in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Non-inferiority Analysis
Timepoint [23] 0 0
Week 28 to end of study (4.3 person-years for follow-up time period)
Secondary outcome [24] 0 0
Percentage of Time With Hemoglobin in the Analysis Range (10 to 11.5 Grams/Deciliter) During Maintenance Period (Week 28 to End of Study): Superiority Analysis
Timepoint [24] 0 0
Week 28 to end of study (4.3 person-years for follow-up time period)
Secondary outcome [25] 0 0
Change From Baseline in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP) and Mean Arterial Blood Pressure (MAP) at Week 52
Timepoint [25] 0 0
Baseline (Week -4) and Week 52
Secondary outcome [26] 0 0
Change From Baseline in SBP, DBP, MAP at End of Treatment
Timepoint [26] 0 0
Baseline (Week -4) and 51.1 months
Secondary outcome [27] 0 0
Blood Pressure (BP) Exacerbation Event Rate Per 100 Participant Years
Timepoint [27] 0 0
Day 1 to end of treatment (51.1 months)
Secondary outcome [28] 0 0
Number of Participants With at Least One BP Exacerbation Event During Study
Timepoint [28] 0 0
Day 1 to end of treatment (51.1 months)
Secondary outcome [29] 0 0
Percentage of Participants Permanently Stopping Randomized Treatment Due to Meeting Rescue Criteria
Timepoint [29] 0 0
Day 1 to 51.1 months
Secondary outcome [30] 0 0
Change From Baseline in On-treatment Physical Component Score (PCS) Using Short Form (SF)-36 Health-related Quality of Life (HRQoL) Questionnaire at Weeks 8, 12, 28, 52
Timepoint [30] 0 0
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Secondary outcome [31] 0 0
Change From Baseline in On-treatment Mental Component Score (MCS) Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
Timepoint [31] 0 0
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Secondary outcome [32] 0 0
Change From Baseline in On-treatment SF-36 HRQoL Scores for Bodily Pain, General Health, Mental Health, Role-Emotional, Role-Physical, Social Functioning at Weeks 8, 12, 28, 52
Timepoint [32] 0 0
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Secondary outcome [33] 0 0
Change From Baseline in On-treatment Vitality Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
Timepoint [33] 0 0
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Secondary outcome [34] 0 0
Change From Baseline in On-treatment Physical Functioning Domain Scores Using SF-36 HRQoL Questionnaire at Weeks 8, 12, 28, 52
Timepoint [34] 0 0
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Secondary outcome [35] 0 0
Change From Baseline in On-treatment Health Utility EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Questionnaire Score at Week 52
Timepoint [35] 0 0
Baseline (Pre-dose on Day 1) and Week 52
Secondary outcome [36] 0 0
Change From Baseline in On-treatment EQ Visual Analogue Scale (EQ-VAS) at Week 52
Timepoint [36] 0 0
Baseline (Pre-dose on Day 1) and Week 52
Secondary outcome [37] 0 0
Change From Baseline in On-treatment Chronic Kidney Disease- Anemia Symptoms Questionnaire (CKD-AQ) at Weeks 8, 12, 28, 52
Timepoint [37] 0 0
Baseline (Day 1) and Weeks 8, 12, 28, 52
Secondary outcome [38] 0 0
Change From Baseline in On-treatment Patient Global Impression of Severity (PGI-S) at Weeks 8, 12, 28, 52
Timepoint [38] 0 0
Baseline (Pre-dose on Day 1), Weeks 8, 12, 28 and 52
Secondary outcome [39] 0 0
Change From Baseline in Post-randomization Estimated Glomerular Filtration Rate (eGFR) at Week 52
Timepoint [39] 0 0
Baseline (Pre-dose on Day 1) and Week 52

Eligibility
Key inclusion criteria
* Age: 18 to 99 years of age (inclusive)
* CKD stage: Kidney Disease Outcomes Quality Initiative (KDOQI) CKD stages 3, 4, or 5 defined by electronic eGFR using the CKD Epidemiology Collaboration (CKD-EPI) formula.
* Erythropoietin-stimulating agents (ESAs)/Hgb: Group 1 (not using ESAs): No ESA use within the 6 weeks prior to screening and no ESA use between screening and randomization (Day 1). Group 2 (ESA users): Use of any approved ESA for the 6 weeks prior to screening and continuing between screening and randomization.
* For Group 1 (not using ESAs), Hgb concentration at Week -8 and Week 1 should be 8 to 10 gram per deciliter (g/dL). For Group 2 (ESA users), Hgb concentration at Week -8 should be 8 to 12 g/dL and at Week 1 should be 8 to 11 g/dL.
* >=80% and <=120% compliance with placebo during run-in period.
* Informed consent (screening only): capable of giving signed informed consent which includes compliance with the requirements and restrictions.
Minimum age
18 Years
Maximum age
99 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Dialysis: On dialysis or clinical evidence of impending need to initiate dialysis within 90 days after study start (Day 1).
* Kidney transplant: Planned living-related or living-unrelated kidney transplant within 52 weeks after study start (Day 1).
* Ferritin: <=100 nanograms (ng)/milliliter (mL) (<=100 micrograms/liter [L]) at screening.
* Transferrin saturation (TSAT) (screening only): <=20%.
* Aplasias: History of bone marrow aplasia or pure red cell aplasia.
* Other causes of anemia: untreated pernicious anemia, thalassemia major, sickle cell disease or myelodysplastic syndrome.
* Gastrointestinal (GI) bleeding: Evidence of actively bleeding gastric, duodenal, or esophageal ulcer disease or clinically significant GI bleeding <=4 weeks prior to screening through to randomization (Day 1).
* MI or acute coronary syndrome: <=4 weeks prior to screening through to randomization (Day 1).
* Stroke or transient ischemic attack: <=4 weeks prior to screening through to randomization (Day 1).
* Heart failure (HF): Chronic Class IV HF, as defined by the New York Heart Association (NYHA) functional classification system.
* Current uncontrolled hypertension: Current uncontrolled hypertension as determined by the investigator.
* Bazett's corrected QT interval (QTcB) (Day 1): QTcB >500 millisecond (msec), or QTcB >530 msec in subjects with bundle branch block. There is no Q-T Interval Corrected for Heart Rate (QTc) exclusion for subjects with a predominantly ventricular paced rhythm.
* Alanine transaminase (ALT): >2x upper limit of normal (ULN) at screening.
* Bilirubin: >1.5xULN at screening.
* Current unstable liver or biliary disease per investigator assessment, generally defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
* Malignancy: History of malignancy within the 2 years prior to screening through to randomization (Day 1) or currently receiving treatment for cancer, or complex kidney cyst (example [e.g.] Bosniak Category II F, III or IV) > 3 centimeter (cm); with the exception of localized squamous cell or basal cell carcinoma of the skin that has been definitively treated >=4 weeks prior to screening.
* Severe allergic reactions: History of severe allergic or anaphylactic reactions or hypersensitivity to excipients in the investigational product, or darbepoetin alfa.
* Drugs and supplements: Use of strong inhibitors of Cytochrome P4502C8 (CYP2C8) (e.g., gemfibrozil) or strong inducers of CYP2C8 (e.g., rifampin/rifampicin).
* Other study participation: Use of other investigational agent or device prior to screening through to randomization (Day 1). At screening, this exclusion applies to use of the investigational agent within 30 days or within five half lives (whichever is longer).
* Prior treatment with daprodustat: Any prior treatment with daprodustat for treatment duration of >30 days.
* Females only: Subject is pregnant [as confirmed by a positive urine human chorionic gonadotrophin (hCG) test for females of reproductive potential (FRP) only], subject is breastfeeding, or subject is of reproductive potential and does not agree to follow one of the contraceptive options.
* Other Conditions: Any other condition, clinical or laboratory abnormality, or examination finding that the investigator considers would put the subject at unacceptable risk, which may affect study compliance (e.g., intolerance to darbepoetin alfa) or prevent understanding of the aims or investigational procedures or possible consequences of the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
27/09/2016
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/04/2021
Sample size
Target
Accrual to date
Final
3872
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
GSK Investigational Site - Garran
Recruitment hospital [2] 0 0
GSK Investigational Site - Concord
Recruitment hospital [3] 0 0
GSK Investigational Site - Gosford
Recruitment hospital [4] 0 0
GSK Investigational Site - Kingswood
Recruitment hospital [5] 0 0
GSK Investigational Site - Kogarah
Recruitment hospital [6] 0 0
GSK Investigational Site - Randwick
Recruitment hospital [7] 0 0
GSK Investigational Site - St Leonards
Recruitment hospital [8] 0 0
GSK Investigational Site - Wollongong
Recruitment hospital [9] 0 0
GSK Investigational Site - Nambour
Recruitment hospital [10] 0 0
GSK Investigational Site - Melbourne
Recruitment hospital [11] 0 0
GSK Investigational Site - Reservoir
Recruitment hospital [12] 0 0
GSK Investigational Site - St Albans
Recruitment hospital [13] 0 0
GSK Investigational Site - Nedlands
Recruitment hospital [14] 0 0
GSK Investigational Site - Liverpool
Recruitment postcode(s) [1] 0 0
2606 - Garran
Recruitment postcode(s) [2] 0 0
2139 - Concord
Recruitment postcode(s) [3] 0 0
2250 - Gosford
Recruitment postcode(s) [4] 0 0
2747 - Kingswood
Recruitment postcode(s) [5] 0 0
2217 - Kogarah
Recruitment postcode(s) [6] 0 0
2031 - Randwick
Recruitment postcode(s) [7] 0 0
2065 - St Leonards
Recruitment postcode(s) [8] 0 0
2500 - Wollongong
Recruitment postcode(s) [9] 0 0
4560 - Nambour
Recruitment postcode(s) [10] 0 0
3004 - Melbourne
Recruitment postcode(s) [11] 0 0
3073 - Reservoir
Recruitment postcode(s) [12] 0 0
3021 - St Albans
Recruitment postcode(s) [13] 0 0
6009 - Nedlands
Recruitment postcode(s) [14] 0 0
2107 - Liverpool
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Idaho
Country [9] 0 0
United States of America
State/province [9] 0 0
Illinois
Country [10] 0 0
United States of America
State/province [10] 0 0
Indiana
Country [11] 0 0
United States of America
State/province [11] 0 0
Iowa
Country [12] 0 0
United States of America
State/province [12] 0 0
Kansas
Country [13] 0 0
United States of America
State/province [13] 0 0
Kentucky
Country [14] 0 0
United States of America
State/province [14] 0 0
Louisiana
Country [15] 0 0
United States of America
State/province [15] 0 0
Maryland
Country [16] 0 0
United States of America
State/province [16] 0 0
Massachusetts
Country [17] 0 0
United States of America
State/province [17] 0 0
Michigan
Country [18] 0 0
United States of America
State/province [18] 0 0
Minnesota
Country [19] 0 0
United States of America
State/province [19] 0 0
Mississippi
Country [20] 0 0
United States of America
State/province [20] 0 0
Missouri
Country [21] 0 0
United States of America
State/province [21] 0 0
Nebraska
Country [22] 0 0
United States of America
State/province [22] 0 0
Nevada
Country [23] 0 0
United States of America
State/province [23] 0 0
New York
Country [24] 0 0
United States of America
State/province [24] 0 0
North Carolina
Country [25] 0 0
United States of America
State/province [25] 0 0
North Dakota
Country [26] 0 0
United States of America
State/province [26] 0 0
Ohio
Country [27] 0 0
United States of America
State/province [27] 0 0
Oklahoma
Country [28] 0 0
United States of America
State/province [28] 0 0
Oregon
Country [29] 0 0
United States of America
State/province [29] 0 0
Pennsylvania
Country [30] 0 0
United States of America
State/province [30] 0 0
South Carolina
Country [31] 0 0
United States of America
State/province [31] 0 0
Tennessee
Country [32] 0 0
United States of America
State/province [32] 0 0
Texas
Country [33] 0 0
United States of America
State/province [33] 0 0
Virginia
Country [34] 0 0
United States of America
State/province [34] 0 0
West Virginia
Country [35] 0 0
Argentina
State/province [35] 0 0
Buenos Aires
Country [36] 0 0
Argentina
State/province [36] 0 0
Córdova
Country [37] 0 0
Argentina
State/province [37] 0 0
Corrientes
Country [38] 0 0
Argentina
State/province [38] 0 0
Formosa
Country [39] 0 0
Argentina
State/province [39] 0 0
La Plata
Country [40] 0 0
Argentina
State/province [40] 0 0
Mendoza
Country [41] 0 0
Argentina
State/province [41] 0 0
Moron
Country [42] 0 0
Argentina
State/province [42] 0 0
San Miguel de Tucumán
Country [43] 0 0
Belgium
State/province [43] 0 0
Aalst
Country [44] 0 0
Belgium
State/province [44] 0 0
Baudour
Country [45] 0 0
Belgium
State/province [45] 0 0
Brugge
Country [46] 0 0
Belgium
State/province [46] 0 0
Brussels
Country [47] 0 0
Belgium
State/province [47] 0 0
Ieper
Country [48] 0 0
Belgium
State/province [48] 0 0
Leuven
Country [49] 0 0
Belgium
State/province [49] 0 0
Liège
Country [50] 0 0
Belgium
State/province [50] 0 0
Roeselare
Country [51] 0 0
Belgium
State/province [51] 0 0
Ronse
Country [52] 0 0
Belgium
State/province [52] 0 0
Sint-Niklaas
Country [53] 0 0
Brazil
State/province [53] 0 0
Bahia
Country [54] 0 0
Brazil
State/province [54] 0 0
Paraná
Country [55] 0 0
Brazil
State/province [55] 0 0
Rio Grande Do Sul
Country [56] 0 0
Brazil
State/province [56] 0 0
São Paulo
Country [57] 0 0
Brazil
State/province [57] 0 0
Belo Horizonte
Country [58] 0 0
Brazil
State/province [58] 0 0
Brasilia
Country [59] 0 0
Brazil
State/province [59] 0 0
Feira de Santana
Country [60] 0 0
Brazil
State/province [60] 0 0
Joinville
Country [61] 0 0
Brazil
State/province [61] 0 0
Juiz De Fora
Country [62] 0 0
Brazil
State/province [62] 0 0
Sao Paulo
Country [63] 0 0
Bulgaria
State/province [63] 0 0
Blagoevgrad
Country [64] 0 0
Bulgaria
State/province [64] 0 0
Burgas
Country [65] 0 0
Bulgaria
State/province [65] 0 0
Dobrich
Country [66] 0 0
Bulgaria
State/province [66] 0 0
Gabrovo
Country [67] 0 0
Bulgaria
State/province [67] 0 0
Lom
Country [68] 0 0
Bulgaria
State/province [68] 0 0
Pazardzhik
Country [69] 0 0
Bulgaria
State/province [69] 0 0
Plovdiv
Country [70] 0 0
Bulgaria
State/province [70] 0 0
Sliven
Country [71] 0 0
Bulgaria
State/province [71] 0 0
Smolyan
Country [72] 0 0
Bulgaria
State/province [72] 0 0
Sofia
Country [73] 0 0
Bulgaria
State/province [73] 0 0
Stara Zagora
Country [74] 0 0
Bulgaria
State/province [74] 0 0
Varna
Country [75] 0 0
Bulgaria
State/province [75] 0 0
Veliko Tarnovo
Country [76] 0 0
Canada
State/province [76] 0 0
Alberta
Country [77] 0 0
Canada
State/province [77] 0 0
Nova Scotia
Country [78] 0 0
Canada
State/province [78] 0 0
Ontario
Country [79] 0 0
Canada
State/province [79] 0 0
Quebec
Country [80] 0 0
Colombia
State/province [80] 0 0
Barranquilla
Country [81] 0 0
Colombia
State/province [81] 0 0
Bogotá
Country [82] 0 0
Colombia
State/province [82] 0 0
Cali
Country [83] 0 0
Colombia
State/province [83] 0 0
Floridablanca
Country [84] 0 0
Colombia
State/province [84] 0 0
Medellin
Country [85] 0 0
Czechia
State/province [85] 0 0
Beroun
Country [86] 0 0
Czechia
State/province [86] 0 0
Cesky Krumlov
Country [87] 0 0
Czechia
State/province [87] 0 0
Ivancice
Country [88] 0 0
Czechia
State/province [88] 0 0
Jilemnice
Country [89] 0 0
Czechia
State/province [89] 0 0
Marianske Lazne
Country [90] 0 0
Czechia
State/province [90] 0 0
Novy Jicin
Country [91] 0 0
Czechia
State/province [91] 0 0
Pardubice
Country [92] 0 0
Czechia
State/province [92] 0 0
Praha 2
Country [93] 0 0
Czechia
State/province [93] 0 0
Praha 4
Country [94] 0 0
Czechia
State/province [94] 0 0
Sokolov
Country [95] 0 0
Denmark
State/province [95] 0 0
Aalborg
Country [96] 0 0
Denmark
State/province [96] 0 0
Holstebro
Country [97] 0 0
Denmark
State/province [97] 0 0
Kolding
Country [98] 0 0
Denmark
State/province [98] 0 0
Odense C
Country [99] 0 0
Estonia
State/province [99] 0 0
Jämejala Village
Country [100] 0 0
Estonia
State/province [100] 0 0
Tallinn
Country [101] 0 0
Estonia
State/province [101] 0 0
Tartu
Country [102] 0 0
France
State/province [102] 0 0
Annonay
Country [103] 0 0
France
State/province [103] 0 0
Boulogne Billancourt
Country [104] 0 0
France
State/province [104] 0 0
Caen Cedex 9
Country [105] 0 0
France
State/province [105] 0 0
Clermont-Ferrand
Country [106] 0 0
France
State/province [106] 0 0
Lyon
Country [107] 0 0
France
State/province [107] 0 0
Montpellier
Country [108] 0 0
France
State/province [108] 0 0
Mulhouse
Country [109] 0 0
France
State/province [109] 0 0
Poitiers
Country [110] 0 0
France
State/province [110] 0 0
Saint-Ouen
Country [111] 0 0
Germany
State/province [111] 0 0
Baden-Wuerttemberg
Country [112] 0 0
Germany
State/province [112] 0 0
Bayern
Country [113] 0 0
Germany
State/province [113] 0 0
Niedersachsen
Country [114] 0 0
Germany
State/province [114] 0 0
Nordrhein-Westfalen
Country [115] 0 0
Germany
State/province [115] 0 0
Rheinland-Pfalz
Country [116] 0 0
Germany
State/province [116] 0 0
Sachsen
Country [117] 0 0
Germany
State/province [117] 0 0
Koeln
Country [118] 0 0
Germany
State/province [118] 0 0
Wiesbaden
Country [119] 0 0
Greece
State/province [119] 0 0
Alexandroupolis
Country [120] 0 0
Greece
State/province [120] 0 0
Arta
Country [121] 0 0
Greece
State/province [121] 0 0
Athens
Country [122] 0 0
Greece
State/province [122] 0 0
Efkarpia
Country [123] 0 0
Greece
State/province [123] 0 0
Heraklion-Crete
Country [124] 0 0
Greece
State/province [124] 0 0
Ioannina
Country [125] 0 0
Greece
State/province [125] 0 0
Komotini
Country [126] 0 0
Greece
State/province [126] 0 0
Larissa
Country [127] 0 0
Greece
State/province [127] 0 0
Melissia
Country [128] 0 0
Greece
State/province [128] 0 0
Patras
Country [129] 0 0
Greece
State/province [129] 0 0
Thessaloniki
Country [130] 0 0
Hong Kong
State/province [130] 0 0
Hong Kong
Country [131] 0 0
Hong Kong
State/province [131] 0 0
Lai Chi kok
Country [132] 0 0
Hong Kong
State/province [132] 0 0
New Territories
Country [133] 0 0
Hong Kong
State/province [133] 0 0
Tsuen Wan
Country [134] 0 0
Hungary
State/province [134] 0 0
Baja
Country [135] 0 0
Hungary
State/province [135] 0 0
Balatonfured
Country [136] 0 0
Hungary
State/province [136] 0 0
Esztergom
Country [137] 0 0
Hungary
State/province [137] 0 0
Kecskemét
Country [138] 0 0
Hungary
State/province [138] 0 0
Miskolc
Country [139] 0 0
Hungary
State/province [139] 0 0
Pecs
Country [140] 0 0
Hungary
State/province [140] 0 0
Salgótarján
Country [141] 0 0
Hungary
State/province [141] 0 0
Szigetvar
Country [142] 0 0
India
State/province [142] 0 0
Ahmedabad
Country [143] 0 0
India
State/province [143] 0 0
Bangalore
Country [144] 0 0
India
State/province [144] 0 0
Calicut
Country [145] 0 0
India
State/province [145] 0 0
Chandigarh
Country [146] 0 0
India
State/province [146] 0 0
Chennai, Tamil Nadu
Country [147] 0 0
India
State/province [147] 0 0
Chennai
Country [148] 0 0
India
State/province [148] 0 0
Delhi
Country [149] 0 0
India
State/province [149] 0 0
Ghaziabad
Country [150] 0 0
India
State/province [150] 0 0
Gurgaon
Country [151] 0 0
India
State/province [151] 0 0
Hyderabad
Country [152] 0 0
India
State/province [152] 0 0
Jaipur
Country [153] 0 0
India
State/province [153] 0 0
Lucknow
Country [154] 0 0
India
State/province [154] 0 0
Manipal
Country [155] 0 0
India
State/province [155] 0 0
Mumbai
Country [156] 0 0
India
State/province [156] 0 0
Nadiad
Country [157] 0 0
India
State/province [157] 0 0
Nagpur
Country [158] 0 0
India
State/province [158] 0 0
New Delhi
Country [159] 0 0
India
State/province [159] 0 0
Pune
Country [160] 0 0
India
State/province [160] 0 0
Secunderabad
Country [161] 0 0
India
State/province [161] 0 0
Trivandrum
Country [162] 0 0
Israel
State/province [162] 0 0
Ashkelon
Country [163] 0 0
Israel
State/province [163] 0 0
Hadera
Country [164] 0 0
Israel
State/province [164] 0 0
Haifa
Country [165] 0 0
Israel
State/province [165] 0 0
Kfar Saba
Country [166] 0 0
Israel
State/province [166] 0 0
Nahariya
Country [167] 0 0
Israel
State/province [167] 0 0
Nazareth
Country [168] 0 0
Israel
State/province [168] 0 0
Poriya
Country [169] 0 0
Israel
State/province [169] 0 0
Zerifin
Country [170] 0 0
Italy
State/province [170] 0 0
Calabria
Country [171] 0 0
Italy
State/province [171] 0 0
Campania
Country [172] 0 0
Italy
State/province [172] 0 0
Emilia-Romagna
Country [173] 0 0
Italy
State/province [173] 0 0
Liguria
Country [174] 0 0
Italy
State/province [174] 0 0
Lombardia
Country [175] 0 0
Italy
State/province [175] 0 0
Piemonte
Country [176] 0 0
Italy
State/province [176] 0 0
Puglia
Country [177] 0 0
Italy
State/province [177] 0 0
Sardegna
Country [178] 0 0
Italy
State/province [178] 0 0
Imola
Country [179] 0 0
Italy
State/province [179] 0 0
Mestre
Country [180] 0 0
Korea, Republic of
State/province [180] 0 0
Anyang-Si, Gyeonggi-do
Country [181] 0 0
Korea, Republic of
State/province [181] 0 0
Bucheon
Country [182] 0 0
Korea, Republic of
State/province [182] 0 0
Busan
Country [183] 0 0
Korea, Republic of
State/province [183] 0 0
Daegu
Country [184] 0 0
Korea, Republic of
State/province [184] 0 0
Daejeon
Country [185] 0 0
Korea, Republic of
State/province [185] 0 0
Goyang-si
Country [186] 0 0
Korea, Republic of
State/province [186] 0 0
Ilsanseo-gu, Goyang-si,
Country [187] 0 0
Korea, Republic of
State/province [187] 0 0
Incheon
Country [188] 0 0
Korea, Republic of
State/province [188] 0 0
Jeonju-si
Country [189] 0 0
Korea, Republic of
State/province [189] 0 0
Seongnam
Country [190] 0 0
Korea, Republic of
State/province [190] 0 0
Seoul
Country [191] 0 0
Korea, Republic of
State/province [191] 0 0
Suwon
Country [192] 0 0
Korea, Republic of
State/province [192] 0 0
Uijeongbu-si
Country [193] 0 0
Korea, Republic of
State/province [193] 0 0
Wonju-si
Country [194] 0 0
Malaysia
State/province [194] 0 0
Alor Setar
Country [195] 0 0
Malaysia
State/province [195] 0 0
Ipoh
Country [196] 0 0
Malaysia
State/province [196] 0 0
Kuala Lumpur
Country [197] 0 0
Malaysia
State/province [197] 0 0
Kuantan
Country [198] 0 0
Malaysia
State/province [198] 0 0
Lumut
Country [199] 0 0
Malaysia
State/province [199] 0 0
Pahang
Country [200] 0 0
Malaysia
State/province [200] 0 0
Penang
Country [201] 0 0
Mexico
State/province [201] 0 0
Coahuila
Country [202] 0 0
Mexico
State/province [202] 0 0
Durango
Country [203] 0 0
Mexico
State/province [203] 0 0
Estado De México
Country [204] 0 0
Mexico
State/province [204] 0 0
Guanajuato
Country [205] 0 0
Mexico
State/province [205] 0 0
Jalisco
Country [206] 0 0
Mexico
State/province [206] 0 0
Morelos
Country [207] 0 0
Mexico
State/province [207] 0 0
Nuevo León
Country [208] 0 0
Mexico
State/province [208] 0 0
Querétaro
Country [209] 0 0
Mexico
State/province [209] 0 0
Sinaloa
Country [210] 0 0
Mexico
State/province [210] 0 0
Yucatán
Country [211] 0 0
Mexico
State/province [211] 0 0
Aguascalientes
Country [212] 0 0
Mexico
State/province [212] 0 0
Chihuahua
Country [213] 0 0
Mexico
State/province [213] 0 0
Ciudad De México
Country [214] 0 0
Mexico
State/province [214] 0 0
Culiacan
Country [215] 0 0
Mexico
State/province [215] 0 0
Tlalnepantla De Baz
Country [216] 0 0
Mexico
State/province [216] 0 0
Veracruz
Country [217] 0 0
Mexico
State/province [217] 0 0
Zapopan, Jalisco
Country [218] 0 0
Netherlands
State/province [218] 0 0
Amsterdam
Country [219] 0 0
Netherlands
State/province [219] 0 0
Deventer
Country [220] 0 0
Netherlands
State/province [220] 0 0
Rotterdam
Country [221] 0 0
New Zealand
State/province [221] 0 0
Dunedin
Country [222] 0 0
New Zealand
State/province [222] 0 0
Hamilton
Country [223] 0 0
New Zealand
State/province [223] 0 0
Hastings
Country [224] 0 0
New Zealand
State/province [224] 0 0
Otahuhu
Country [225] 0 0
New Zealand
State/province [225] 0 0
Takapuna, Auckland
Country [226] 0 0
Philippines
State/province [226] 0 0
Baguio City, Benguet
Country [227] 0 0
Philippines
State/province [227] 0 0
Cebu City
Country [228] 0 0
Philippines
State/province [228] 0 0
Dasmarinas
Country [229] 0 0
Philippines
State/province [229] 0 0
Iloilo City
Country [230] 0 0
Philippines
State/province [230] 0 0
Manila
Country [231] 0 0
Philippines
State/province [231] 0 0
Pasig
Country [232] 0 0
Philippines
State/province [232] 0 0
Quezon City
Country [233] 0 0
Philippines
State/province [233] 0 0
San Juan
Country [234] 0 0
Philippines
State/province [234] 0 0
Sto Tomas
Country [235] 0 0
Poland
State/province [235] 0 0
Bialystok
Country [236] 0 0
Poland
State/province [236] 0 0
Brzeg
Country [237] 0 0
Poland
State/province [237] 0 0
Gdansk
Country [238] 0 0
Poland
State/province [238] 0 0
Katowice
Country [239] 0 0
Poland
State/province [239] 0 0
Kielce
Country [240] 0 0
Poland
State/province [240] 0 0
Kolobrzeg
Country [241] 0 0
Poland
State/province [241] 0 0
Lodz
Country [242] 0 0
Poland
State/province [242] 0 0
Radom
Country [243] 0 0
Poland
State/province [243] 0 0
Szczecin
Country [244] 0 0
Poland
State/province [244] 0 0
Zyrardow
Country [245] 0 0
Portugal
State/province [245] 0 0
Amadora
Country [246] 0 0
Portugal
State/province [246] 0 0
Aveiro
Country [247] 0 0
Portugal
State/province [247] 0 0
Covilhã
Country [248] 0 0
Portugal
State/province [248] 0 0
Lisboa
Country [249] 0 0
Portugal
State/province [249] 0 0
Torres Novas
Country [250] 0 0
Romania
State/province [250] 0 0
Bucharest
Country [251] 0 0
Romania
State/province [251] 0 0
Bucuresti
Country [252] 0 0
Romania
State/province [252] 0 0
Constanta
Country [253] 0 0
Romania
State/province [253] 0 0
Oradea
Country [254] 0 0
Romania
State/province [254] 0 0
Timisoara
Country [255] 0 0
Russian Federation
State/province [255] 0 0
Irkutsk
Country [256] 0 0
Russian Federation
State/province [256] 0 0
Kemerovo
Country [257] 0 0
Russian Federation
State/province [257] 0 0
Krasnodar
Country [258] 0 0
Russian Federation
State/province [258] 0 0
Moscow
Country [259] 0 0
Russian Federation
State/province [259] 0 0
Mytischi
Country [260] 0 0
Russian Federation
State/province [260] 0 0
Omsk
Country [261] 0 0
Russian Federation
State/province [261] 0 0
Podolsk
Country [262] 0 0
Russian Federation
State/province [262] 0 0
Ryazan
Country [263] 0 0
Russian Federation
State/province [263] 0 0
Smolensk
Country [264] 0 0
Russian Federation
State/province [264] 0 0
St. Petersburg
Country [265] 0 0
Russian Federation
State/province [265] 0 0
Ulyanovsk
Country [266] 0 0
Russian Federation
State/province [266] 0 0
Volzhsky
Country [267] 0 0
Russian Federation
State/province [267] 0 0
Yaroslavl
Country [268] 0 0
Singapore
State/province [268] 0 0
Singapore
Country [269] 0 0
South Africa
State/province [269] 0 0
Eastern Cape
Country [270] 0 0
South Africa
State/province [270] 0 0
Cape Town.
Country [271] 0 0
South Africa
State/province [271] 0 0
Cape Town
Country [272] 0 0
South Africa
State/province [272] 0 0
Somerset West
Country [273] 0 0
Spain
State/province [273] 0 0
Madrid
Country [274] 0 0
Spain
State/province [274] 0 0
Badalona
Country [275] 0 0
Spain
State/province [275] 0 0
Barcelona
Country [276] 0 0
Spain
State/province [276] 0 0
Burela
Country [277] 0 0
Spain
State/province [277] 0 0
Caceres
Country [278] 0 0
Spain
State/province [278] 0 0
Ciudad Real
Country [279] 0 0
Spain
State/province [279] 0 0
Girona
Country [280] 0 0
Spain
State/province [280] 0 0
Guadalajara
Country [281] 0 0
Spain
State/province [281] 0 0
L'Hospitalet de Llobregat
Country [282] 0 0
Spain
State/province [282] 0 0
Mollet del Valles
Country [283] 0 0
Spain
State/province [283] 0 0
Santiago de Compostela
Country [284] 0 0
Spain
State/province [284] 0 0
Sevilla
Country [285] 0 0
Sweden
State/province [285] 0 0
Stockholm
Country [286] 0 0
Sweden
State/province [286] 0 0
Uppsala
Country [287] 0 0
Sweden
State/province [287] 0 0
Örebro
Country [288] 0 0
Taiwan
State/province [288] 0 0
Kaohsiung
Country [289] 0 0
Taiwan
State/province [289] 0 0
Keelung
Country [290] 0 0
Taiwan
State/province [290] 0 0
New Taipei
Country [291] 0 0
Taiwan
State/province [291] 0 0
Tainan
Country [292] 0 0
Taiwan
State/province [292] 0 0
Taipei
Country [293] 0 0
Taiwan
State/province [293] 0 0
Taoyuan Hsien
Country [294] 0 0
Thailand
State/province [294] 0 0
Bangkoknoi
Country [295] 0 0
Thailand
State/province [295] 0 0
Bangkok
Country [296] 0 0
Thailand
State/province [296] 0 0
Chiang Mai
Country [297] 0 0
Thailand
State/province [297] 0 0
Khon Kaen
Country [298] 0 0
Thailand
State/province [298] 0 0
Pathumthani
Country [299] 0 0
Turkey
State/province [299] 0 0
Adana
Country [300] 0 0
Turkey
State/province [300] 0 0
Ankara
Country [301] 0 0
Turkey
State/province [301] 0 0
Antalya
Country [302] 0 0
Turkey
State/province [302] 0 0
Edirne
Country [303] 0 0
Turkey
State/province [303] 0 0
Eskisehir
Country [304] 0 0
Turkey
State/province [304] 0 0
Istanbul
Country [305] 0 0
Turkey
State/province [305] 0 0
Kayseri
Country [306] 0 0
Ukraine
State/province [306] 0 0
Cherkasy
Country [307] 0 0
Ukraine
State/province [307] 0 0
Chernihiv
Country [308] 0 0
Ukraine
State/province [308] 0 0
Chernivtsi
Country [309] 0 0
Ukraine
State/province [309] 0 0
Ivano-Frankivsk
Country [310] 0 0
Ukraine
State/province [310] 0 0
Kharkiv
Country [311] 0 0
Ukraine
State/province [311] 0 0
Kherson
Country [312] 0 0
Ukraine
State/province [312] 0 0
Kiev
Country [313] 0 0
Ukraine
State/province [313] 0 0
Kyiv
Country [314] 0 0
Ukraine
State/province [314] 0 0
Lutsk
Country [315] 0 0
Ukraine
State/province [315] 0 0
Mykolaiv
Country [316] 0 0
Ukraine
State/province [316] 0 0
Poltava
Country [317] 0 0
Ukraine
State/province [317] 0 0
Ternopil
Country [318] 0 0
Ukraine
State/province [318] 0 0
Zaporizhzhia
Country [319] 0 0
Ukraine
State/province [319] 0 0
Zhytomyr
Country [320] 0 0
United Kingdom
State/province [320] 0 0
Hertfordshire
Country [321] 0 0
United Kingdom
State/province [321] 0 0
Lancashire
Country [322] 0 0
United Kingdom
State/province [322] 0 0
London
Country [323] 0 0
United Kingdom
State/province [323] 0 0
Merseyside
Country [324] 0 0
United Kingdom
State/province [324] 0 0
West Midlands
Country [325] 0 0
United Kingdom
State/province [325] 0 0
Birmingham
Country [326] 0 0
United Kingdom
State/province [326] 0 0
Bristol
Country [327] 0 0
United Kingdom
State/province [327] 0 0
Cambridge
Country [328] 0 0
United Kingdom
State/province [328] 0 0
Cardiff
Country [329] 0 0
United Kingdom
State/province [329] 0 0
Derby
Country [330] 0 0
United Kingdom
State/province [330] 0 0
Doncaster
Country [331] 0 0
United Kingdom
State/province [331] 0 0
Fife
Country [332] 0 0
United Kingdom
State/province [332] 0 0
Glasgow.
Country [333] 0 0
United Kingdom
State/province [333] 0 0
Hull
Country [334] 0 0
United Kingdom
State/province [334] 0 0
Leeds
Country [335] 0 0
United Kingdom
State/province [335] 0 0
Manchester
Country [336] 0 0
United Kingdom
State/province [336] 0 0
Middlesbrough
Country [337] 0 0
United Kingdom
State/province [337] 0 0
Oxford
Country [338] 0 0
United Kingdom
State/province [338] 0 0
Salford
Country [339] 0 0
United Kingdom
State/province [339] 0 0
York
Country [340] 0 0
Vietnam
State/province [340] 0 0
Ha Noi City
Country [341] 0 0
Vietnam
State/province [341] 0 0
Ha Noi
Country [342] 0 0
Vietnam
State/province [342] 0 0
Hai Phong
Country [343] 0 0
Vietnam
State/province [343] 0 0
Hanoi
Country [344] 0 0
Vietnam
State/province [344] 0 0
Ho Chi Minh City
Country [345] 0 0
Vietnam
State/province [345] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
GlaxoSmithKline
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this multi-center event-driven study in non-dialysis (ND) participants with anemia associated with chronic kidney disease (CKD) is to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
Trial website
https://clinicaltrials.gov/study/NCT02876835
Trial related presentations / publications
Ajay K. Singh, Kevin Carroll, John J. V. McMurray, Scott Solomon, Vivekanand Jha, Kirsten L. Johansen, Renato D. Lopes, Iain C. Macdougall, Gregorio T. Obrador, Sushrut S. Waikar, Christoph Wanner, David C. Wheeler, Andrzej Wiecek, Allison Blackorby, Borut Cizman, Alexander R. Cobitz, Rich Davies, Tara L. DiMino, Lata Kler, Amy M. Meadowcroft, Lin Taft, Vlado Perkovic for the ASCEND-ND Study Group. DAPRODUSTAT FOR THE TREATMENT OF ANEMIA IN PATIENTS NOT UNDERGOING DIALYSIS. N Engl J Med. 2021; DOI: 10.1056/NEJMoa2113380 PMID: 34739196
Perkovic V, Blackorby A, Cizman B, Carroll K, Cobitz AR, Davies R, DiMino TL, Jha V, Johansen KL, Lopes RD, Kler L, Macdougall IC, McMurray JJV, Meadowcroft AM, Obrador GT, Solomon S, Taft L, Wanner C, Waikar SS, Wheeler DC, Wiecek A, Singh AK. The ASCEND-ND trial: study design and participant characteristics. Nephrol Dial Transplant. 2022 Oct 19;37(11):2157-2170. doi: 10.1093/ndt/gfab318.
Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2.
Singh AK, Carroll K, McMurray JJV, Solomon S, Jha V, Johansen KL, Lopes RD, Macdougall IC, Obrador GT, Waikar SS, Wanner C, Wheeler DC, Wiecek A, Blackorby A, Cizman B, Cobitz AR, Davies R, DiMino TL, Kler L, Meadowcroft AM, Taft L, Perkovic V; ASCEND-ND Study Group. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. N Engl J Med. 2021 Dec 16;385(25):2313-2324. doi: 10.1056/NEJMoa2113380. Epub 2021 Nov 5.
Public notes

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
GlaxoSmithKline
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02876835